Financial News
Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst
May 05, 2023 at 10:49 AM EDT
--News Direct--
Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new research note on clinical-stage biopharmaceutical company Tiziana Life Sciences Ltd (NASDAQ: TLSA). Tiziana has disclosed plans to file INDs (Investigational New Drug applications) aiming to expand the clinical indications of its lead product, intranasal foralumab, into mild-to-moderate Alzheimer’s Disease (AD) and long COVID-19.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
View source version on newsdirect.com: https://newsdirect.com/news/tiziana-life-sciences-expansion-into-new-clinical-indications-proactive-research-analyst-254277864
More News
View More
Tesla’s Robotaxi Goes Unsupervised: Is the Rally Justified? ↗
January 22, 2026
UAL Stock Taking Flight After Earnings Confirm Strong Demand ↗
January 22, 2026
Why Apple’s Sell-Off May Be Overdone Right Before Earnings ↗
January 22, 2026
Qualcomm Gets Crushed: $150 Is the Level to Watch Going Forward ↗
January 22, 2026
Recent Quotes
View More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
